In the only study to include non-AD subjects, high agreement was found between the [18F]AV1451 standardized uptake value ratio and CSF p-tau measurements in differentiating the non-AD subjects from amyloid-β-positive AD patients, suggesting that these measures are largely reflective of AD-specific PHF tau pathology [186]. Here, MAPT is linked to Alzheimer disease.